The decade-long gap that just closed
Addyi was approved for premenopausal women in 2015, after a controversial FDA review that had initially rejected it twice. It was the first drug approved for hypoactive sexual desire disorder in women — a condition affecting roughly one in three postmenopausal women. Then it did nothing for postmenopausal women, because it wasn't approved for them.
That gap closed in December 2025. The FDA's expansion now includes postmenopausal women under 65, based on clinical trial data showing efficacy and safety in this population. The approval is genuinely significant from a medical recognition standpoint: low sexual desire in postmenopausal women is a medical condition, not an inevitable and untreatable consequence of aging.
How flibanserin works — and what it doesn't do
Flibanserin is a serotonin 1A receptor agonist and serotonin 2A receptor antagonist. It also has some dopamine D4 receptor activity. In plain terms: it modulates the balance of neurochemicals involved in sexual desire in the brain, shifting the balance away from serotonin (which suppresses desire) toward dopamine (which drives motivation and pleasure).
This is meaningfully different from testosterone therapy, which addresses the hormonal side of postmenopausal HSDD. Many postmenopausal women have low desire that is partly hormonal — driven by falling testosterone, vaginal dryness (GSM), reduced genital sensitivity, and other physical changes. Flibanserin doesn't address any of those. It addresses the central, brain-based desire pathway specifically.
The 2025 FDA decision was supported by clinical trial data in postmenopausal women showing statistically significant improvements in satisfying sexual events and reductions in distress associated with low desire. Effect sizes are modest — approximately 0.5 to 1.0 additional satisfying sexual events per month above placebo — similar to what was seen in the original premenopausal approval. The Pharmacy Times coverage of the approval noted that the FDA's decision signals "broader recognition of sexual health in aging women." The 2019 Global Consensus Statement on testosterone therapy for women — from 40+ medical societies — supports testosterone as the most evidence-backed treatment for postmenopausal HSDD with hormonal components, making flibanserin most relevant for women where desire is disrupted at the neurological level rather than the hormonal one.
The alcohol interaction — this is not a minor caveat
Flibanserin carries a REMS (Risk Evaluation and Mitigation Strategy) restriction around alcohol. Combining flibanserin with alcohol causes clinically significant drops in blood pressure and increases fainting risk. In trials, this combination led to serious hypotensive events.
The drug must be taken at bedtime, partly because drowsiness is a side effect and partly to reduce functional impairment. It also interacts significantly with CYP3A4 inhibitors — a class that includes many antifungals (fluconazole), some antibiotics, and grapefruit. Any woman considering flibanserin needs an honest inventory of her regular medication and supplement use before starting.
What to tell your doctor
- Ask your OB-GYN or primary care physician whether your low desire has a hormonal component (check testosterone levels) or a more centrally-driven pattern — the answer guides whether flibanserin, testosterone, or a combination approach makes more sense.
- Review all current medications and supplements for CYP3A4 interactions before starting. This includes common antifungals, certain antibiotics, and some anxiety or depression medications.
- Ask about the alcohol interaction explicitly and honestly assess whether it's compatible with your lifestyle — this is a genuine safety issue, not routine label language.
- Flibanserin takes 4–8 weeks to show effect. If there's no meaningful improvement after 8 weeks of consistent use, discuss discontinuation — the drug isn't universally effective, and continuing indefinitely without benefit isn't warranted.
Flibanserin is approved for postmenopausal women under 65 with acquired, generalized HSDD (not explained by another medical or psychiatric condition, relationship factors, or medication side effects). It is contraindicated with alcohol and significant CYP3A4 inhibitors. Discuss with your OB-GYN, internist, or sexual health specialist whether it's appropriate for your specific situation.
Sources
- Sprout Pharmaceuticals. Historic First in Women's Sexual Health: FDA Grants Approval for Addyi in Postmenopausal Women. PRNewswire. December 15, 2025.
- FDA. FDA Approves Expanded Use of Flibanserin for Hypoactive Sexual Desire Disorder in Women. Contemporary OB/GYN. 2025.
- Pharmacy Times. FDA Approval Signals Broader Recognition of Sexual Health in Aging Women. 2025.
- Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666.
- Clayton AH, et al. Flibanserin: A Potential Treatment for Hypoactive Sexual Desire Disorder in Premenopausal Women. Neuropsychiatr Dis Treat. 2018;14:1731-1737.